Journal overview:

Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies. The Journal publishes 12 double issues per year, including sections on Methods (product testing and development) and Clinical Development (regulatory review, toxicology and commercial development) and covers a wide range of reviews, commentaries and editorials.

​

Benefits of publishing with Human Gene Therapy

• No submission fees

• Latest Impact Factor: 4.2

• Average time to first decision: 21 days

• Expert peer review and editorial oversight of your manuscript from leading specialists in your field

• Zero-embargo Green Open Access policy

• Immediate deposit of your work to PubMed and other indexing services upon publication

• Free 30-day access to share your published research with your networks and colleagues

• Global visibility in more than 170 countries 

 

Journal coverage includes:

• Basic and clinical advances in gene therapy

• Delivery systems

• Cell therapy

• Immunotherapy

• Clinical genome editing

• Small nucleic acid therapeutics, including RNAi

• Clinical trials (including confirmatory or negative results)

• Improvements in vector developments

• Animal models

• Pre-clinical animal/in vitro studies to assess safety of gene and cell therapy products

• Clinical protocols

• Commercial development of gene and cell therapy products

​

As member of the SETGYC your are entitled to free access to the journal. 

Please read more on how to do this here.